ArmaGen taps Big Pharma interest in 'Trojan horse' tech to get drugs into brain
This article was originally published in Scrip
ArmaGen Technologies closed a $17 million Series A venture funding round with contributions from three global pharmaceutical companies and a Japanese investor for the Los Angeles-based company's platform technology designed to get both small and large molecule drugs across the blood-brain barrier (BBB).
You may also be interested in...
The WORLD Symposium Feb. 13 to 16 in San Diego offered everything from basic research through late-stage clinical data in lysosomal diseases, including ArmaGen's blood-brain barrier-crossing treatment for Hurler syndrome and updates from ongoing development programs from rare disease specialists, such as Genzyme, Amicus and Protalix.
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.